Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus placebo after bariatric surgery or medical weight management in adults with type 2 diabetes and obesity
ACTRN12613001069741Phase 3Active, not recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liraglutide in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Northern Sydney Local Health District. Primary endpoint: Change in body weight and anthropometric measures. Started Dec 2013; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ACTRN12613001069741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001069741.